BioWorld

July 22, 2004

ImClone Reports Erbitux Sales Of $71.4M, Plans sBLA Filing

ImClone Systems Inc.'s stock fell 18.9 percent Wednesday even though the firm turned a profit on Erbitux sales and said it intends to request FDA approval of the drug in head and neck cancer. (BioWorld Today) Read More

Alexion Raises $77.5M To Fund Phase III Product Development

Seattle Genetics, Celera Join Up For Discovery Of Cancer Drugs

ConjuChem Raises C$25M In Notes Sale For DAC Compounds

Monitors Say Northfield Trial Of PolyHeme Can Continue

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 9, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...